S&P 500   3,961.00 (+0.69%)
DOW   33,802.62 (+0.61%)
QQQ   283.30 (+0.99%)
AAPL   142.64 (+1.21%)
MSFT   246.82 (+1.00%)
META   115.55 (+1.42%)
GOOGL   93.90 (-1.10%)
AMZN   89.67 (+1.37%)
TSLA   170.97 (-1.76%)
NVDA   167.19 (+3.72%)
NIO   13.19 (+4.85%)
BABA   93.31 (+5.64%)
AMD   70.50 (+0.51%)
T   19.15 (-0.78%)
MU   55.35 (+2.84%)
CGC   3.18 (-1.85%)
F   13.16 (+0.46%)
GE   83.85 (-1.35%)
DIS   92.54 (+0.42%)
AMC   6.22 (+2.81%)
PYPL   75.27 (+1.14%)
PFE   50.82 (+1.15%)
NFLX   308.49 (+0.02%)
S&P 500   3,961.00 (+0.69%)
DOW   33,802.62 (+0.61%)
QQQ   283.30 (+0.99%)
AAPL   142.64 (+1.21%)
MSFT   246.82 (+1.00%)
META   115.55 (+1.42%)
GOOGL   93.90 (-1.10%)
AMZN   89.67 (+1.37%)
TSLA   170.97 (-1.76%)
NVDA   167.19 (+3.72%)
NIO   13.19 (+4.85%)
BABA   93.31 (+5.64%)
AMD   70.50 (+0.51%)
T   19.15 (-0.78%)
MU   55.35 (+2.84%)
CGC   3.18 (-1.85%)
F   13.16 (+0.46%)
GE   83.85 (-1.35%)
DIS   92.54 (+0.42%)
AMC   6.22 (+2.81%)
PYPL   75.27 (+1.14%)
PFE   50.82 (+1.15%)
NFLX   308.49 (+0.02%)
S&P 500   3,961.00 (+0.69%)
DOW   33,802.62 (+0.61%)
QQQ   283.30 (+0.99%)
AAPL   142.64 (+1.21%)
MSFT   246.82 (+1.00%)
META   115.55 (+1.42%)
GOOGL   93.90 (-1.10%)
AMZN   89.67 (+1.37%)
TSLA   170.97 (-1.76%)
NVDA   167.19 (+3.72%)
NIO   13.19 (+4.85%)
BABA   93.31 (+5.64%)
AMD   70.50 (+0.51%)
T   19.15 (-0.78%)
MU   55.35 (+2.84%)
CGC   3.18 (-1.85%)
F   13.16 (+0.46%)
GE   83.85 (-1.35%)
DIS   92.54 (+0.42%)
AMC   6.22 (+2.81%)
PYPL   75.27 (+1.14%)
PFE   50.82 (+1.15%)
NFLX   308.49 (+0.02%)
S&P 500   3,961.00 (+0.69%)
DOW   33,802.62 (+0.61%)
QQQ   283.30 (+0.99%)
AAPL   142.64 (+1.21%)
MSFT   246.82 (+1.00%)
META   115.55 (+1.42%)
GOOGL   93.90 (-1.10%)
AMZN   89.67 (+1.37%)
TSLA   170.97 (-1.76%)
NVDA   167.19 (+3.72%)
NIO   13.19 (+4.85%)
BABA   93.31 (+5.64%)
AMD   70.50 (+0.51%)
T   19.15 (-0.78%)
MU   55.35 (+2.84%)
CGC   3.18 (-1.85%)
F   13.16 (+0.46%)
GE   83.85 (-1.35%)
DIS   92.54 (+0.42%)
AMC   6.22 (+2.81%)
PYPL   75.27 (+1.14%)
PFE   50.82 (+1.15%)
NFLX   308.49 (+0.02%)
OTCMKTS:APLIF

Appili Therapeutics - APLIF Stock Forecast, Price & News

$0.03
0.00 (0.00%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.03
$0.03
50-Day Range
$0.03
$0.06
52-Week Range
$0.03
$0.14
Volume
10,000 shs
Average Volume
15,865 shs
Market Capitalization
$2.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
APLIF stock logo

About Appili Therapeutics (OTCMKTS:APLIF) Stock

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

Receive APLIF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Appili Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APLIF Stock News Headlines

Appili Therapeutics GAAP EPS of -C$0.38
Appili Therapeutics launches securities offering
Aditxt Signs Share Exchange Agreement to Acquire AiPharma
See More Headlines
Receive APLIF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Appili Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

APLIF Company Calendar

Today
12/08/2022
Next Earnings (Estimated)
2/13/2023
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:APLIF
CIK
N/A
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Net Income
$-20,040,000.00
Pretax Margin
-1,417.91%

Debt

Sales & Book Value

Annual Sales
$1.11 million
Book Value
($0.04) per share

Miscellaneous

Free Float
N/A
Market Cap
$2.47 million
Optionable
Not Optionable
Beta
-0.62

Key Executives

  • Dr. Donald D. Cilla Jr.
    M.B.A., Pharm.D., Pharmd, CEO, Pres & Director
  • Mr. Kenneth G. Howling
    Acting Chief Financial Officer
  • Dr. Yoav Golan M.S. (Age 60)
    M.D., MS, Chief Medical Officer
    Comp: $360.27k













APLIF Stock - Frequently Asked Questions

How have APLIF shares performed in 2022?

Appili Therapeutics' stock was trading at $0.09 at the beginning of the year. Since then, APLIF shares have decreased by 61.6% and is now trading at $0.0346.
View the best growth stocks for 2022 here
.

Are investors shorting Appili Therapeutics?

Appili Therapeutics saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 67,200 shares, a decline of 6.9% from the October 31st total of 72,200 shares. Based on an average trading volume of 27,500 shares, the short-interest ratio is presently 2.4 days.
View Appili Therapeutics' Short Interest
.

When is Appili Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023.
View our APLIF earnings forecast
.

What is Appili Therapeutics' stock symbol?

Appili Therapeutics trades on the OTCMKTS under the ticker symbol "APLIF."

How do I buy shares of Appili Therapeutics?

Shares of APLIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Appili Therapeutics' stock price today?

One share of APLIF stock can currently be purchased for approximately $0.03.

How much money does Appili Therapeutics make?

Appili Therapeutics (OTCMKTS:APLIF) has a market capitalization of $2.47 million and generates $1.11 million in revenue each year. The company earns $-20,040,000.00 in net income (profit) each year or ($0.13) on an earnings per share basis.

How can I contact Appili Therapeutics?

Appili Therapeutics' mailing address is 21-1344 SUMMER ST., HALIFAX A5, B3H 0A8. The official website for the company is www.appilitherapeutics.com. The company can be reached via phone at 902-442-4655.

This page (OTCMKTS:APLIF) was last updated on 12/8/2022 by MarketBeat.com Staff